CytoSorbents Corporation (CTSO)
| Market Cap | 402.40M |
| Revenue (ttm) | 36.48M |
| Net Income (ttm) | -11.11M |
| Shares Out | 41.59M |
| EPS (ttm) | -0.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $9.34 |
| Previous Close | $9.21 |
| Change ($) | 0.13 |
| Change (%) | 1.41% |
| Day's Open | 9.21 |
| Day's Range | 9.12 - 9.40 |
| Day's Volume | 215,678 |
| 52-Week Range | 4.00 - 11.55 |
MONMOUTH JUNCTION, N.J., Jan. 21, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...
MONMOUTH JUNCTION, N.J., Jan. 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...
MONMOUTH JUNCTION, N.J., Jan. 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...
MONMOUTH JUNCTION, N.J., Jan. 4, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology ...
MONMOUTH JUNCTION, N.J., Dec. 17, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...
MONMOUTH JUNCTION, N.J., Dec. 9, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology ...
MONMOUTH JUNCTION, N.J., Dec. 2, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader that is commercializing its CytoSorb® blood purification tec...
MONMOUTH JUNCTION, N.J., Nov. 25, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...
MONMOUTH JUNCTION, N.J., Nov. 23, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...
MONMOUTH JUNCTION, N.J., Nov. 12, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...
Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q3 2020 Results - Earnings Call Transcript
MONMOUTH JUNCTION, N.J., Nov. 4, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat d...
MONMOUTH JUNCTION, N.J., Oct. 21, 2020 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to trea...
MONMOUTH JUNCTION, N.J., Oct. 9, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the...
MONMOUTH JUNCTION, N.J., Sept. 21, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technolog...
MONMOUTH JUNCTION, N.J., Sept. 8, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...
MONMOUTH JUNCTION, N.J., Aug. 17, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) has entered into separate agreements with InvoSurg Inc.
Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q2 2020 Results - Earnings Call Transcript
Shares of CytoSorbents (NASDAQ:CTSO) fell 2.15% in after-market trading after the company reported Q2 results.
MONMOUTH JUNCTION, N.J., Aug. 4, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat d...
CytoSorbents (NASDAQ: CTSO) releases its next round of earnings this Tuesday, August 04.
MONMOUTH JUNCTION, N.J., Aug. 3, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat d...
MONMOUTH JUNCTION, N.J., July 31, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that th...
MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...
MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (CTSO), CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® bloo...
MONMOUTH JUNCTION, N.J., July 22, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) (the "Company"), a critical care immunotherapy leader commercializing its CytoSorb® blood purific...
A stock offering overshadowed the company's impressive preliminary second-quarter results.
The S&P 500 closing up 0.8% at 2,251.84 and with the NASDAQ closing up 2.5% at 10,767.09, many investors are wondering how stocks keep rising despite the major recession in the time of a COVID...
MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat d...
MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) (the "Company") a critical care immunotherapy leader commercializing its CytoSorb® blood purifica...
MONMOUTH JUNCTION, N.J., June 29, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat d...
MONMOUTH JUNCTION, N.J., June 24, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat d...
MONMOUTH JUNCTION, N.J., June 9, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that it w...
Below is a list of six companies with promising Covid-19 treatments in various stages of development, and the reasons why I have invested in them.
MONMOUTH JUNCTION, N.J., May 27, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology ...
Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q1 2020 Results - Earnings Call Transcript
Cytosorbents: COVID-19 Has Presented A Bullish Opportunity
Shares of CytoSorbents Corp. CTSO, +28.52% gained 28.7% in trading on Monday following a Food and Drug Administration announcement late on Friday that grants an emergency use authorization to ...
CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q4 2019 Results - Earnings Call Transcript
Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q3 2019 Results - Earnings Call Transcript
Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q2 2019 Results - Earnings Call Transcript
Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q1 2019 Results - Earnings Call Transcript
About CTSO
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary ... [Read more...]
| Industry Medical Devices | Founded 1997 |
| CEO Phillip Chan | Employees 153 |
| Stock Exchange NASDAQ | Ticker Symbol CTSO |
Financial Performance
In 2019, CytoSorbents's revenue was $24.95 million, an increase of 10.87% compared to the previous year's $22.50 million. Losses were -$19.27 million, 11.9% more than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for CytoSorbents stock is "Strong Buy." The 12-month stock price forecast is 14.88, which is an increase of 59.31% from the latest price.